I agree with some of the earlier posters: The 20:400 to 20:40 patient along with many other anecdotal references by ACTC representatives will either be shown to be true, or false. That is why, (IMHO) I believe the management's plan to publish the actual clinical trial results in a peer-reviewed scientific journal article is the wise and the correct course of action. If these patients are real, they will be authenticated by the peer-review process. Then one no longer needs to take the word of a reporter or even an ACTC representative. From my conversations with Ophthalmology docs, improvement in these types of macular degeneration patients NEVER happens. Therefore, even if the treatment does nothing more than simply forestall deterioration in patient's vision loss, ACTC will be a big winner. Given the benign safety data, patients would be lined up demanding FDA approval and also the treatment. And the stock price will be a monumental winner! Do the math. Even though the stock price is very low, the market cap (159 million) is (IMHO) respectable for an up-and-coming biotech startup. In other words, astute investors recognize that there is serious potential value here. And if the treatment really does what has been reported, today's issues of large share base would be instantly insignificant, and it seems to me that any biotech investor would want to own a piece of this story. Do your own DD, and best to all. Coach
Re: 10 years from now.....................................................
Soon ..... real soon, ACTC sheeples will be eating their favorite garden vegetable with steak !
FIGHTERPILOT • May 11, 2011 12:57 PM
Those times are gone and below .30 will not last that much longer. NO BRAINER Anticipation alone will drive the SP higher. Anticipation of a game changer. Just picture this: With every patient, results can be seen in a short time, if the results are positive, overwhelming evidence will accumulate rapidly and lead to FDA approval speed you never have seen before. These are open trials !!!!!! Open trials with results under a microscope. Compare with seeds in your garden, when the plant breaks through the soil and is growing to your favorite vegetable you have with your steak, only totally derailed bashers, super idiots, like the ones we have on this MB, will call this a failure. Bashers are toast !!!! No Brainer !!!!!
I agree 100% with what you posted. It is possible that this could take some time to bring to market. But now is the time to invest for me anyway. I am afraid not be invested and some Big Pharma comes along and does a JV and/or a buyout. Which is possible. All Big Pharmas know that stem cells are the future. ACTC is more advanced than any other company in the U.S.. Results will be published in a peer reviewed Magazine. You have to ask why would they (ACTC) do that? Because they know what they have. My opinion they know what they have. Credibility will be of the essence here and when it is published and they figure out how to proceed with Phase 2 it will definitely bump up! Phase 2 might have stipulations allowing to move through it quicker or jump to phase 3 if certain mild stones are meet. Big money is waiting to get in with the reverse split. But who knows maybe Gary has a trick up sleeve, doing everything possible to show the Big Pharmas they will do what is necessary to go on without them, meaning they need to up the ante. Each mile stone means more money. JMHO
Sentiment: Strong Buy
Re: Therefore, even if the treatment does nothing more than simply forestall deterioration in patient's vision loss, ACTC will be a big winner.
"But even if the trial results are positive, ACT will face enormous challenges in commercializing the technology. The company will have to show the FDA that its RPE cells can slow vision loss in bigger and more expensive clinical trials. And even if the treatment works, storing and distributing the cells, which often have short shelf-lives, is expensive and logistically difficult, says Chris Mason, head of the Stem Cell and Regenerative Medicine Bioprocess Group at University College London."
Re: ............ACT will face enormous challenges in commercializing the technology..................
Remember GERN ? GERN discontinued further development of its " stem cell programs and is seeking partners for their novel assets............ The decision to narrow Geron's technology and therapeutic focus was made after a strategic review of the costs, value inflection timelines and clinical, manufacturing and regulatory complexities associated with the Company's research and clinical-stage assets."
BTW, Geron completed divestiture of their stem cell assets. On January 4, 2013, Geron, entered into an Asset Contribution Agreement with BioTime, Inc. and Asterias Biotherapeutics, Inc.